Glucose Monitoring in Diabetes: Physiological Basis, Modalities, and Limitations of HbA1c

Finger-prick blood glucose testing using a glucometer provides a real-time “snapshot” of blood sugar levels, helping individuals with diabetes monitor and adjust their management in response to immediate changes (Diabetes Ireland).

Introduction

Diabetes mellitus is characterised by chronic hyperglycaemia due to impaired insulin secretion, insulin action, or both. Accurate assessment of glycaemic status is central to preventing microvascular and macrovascular complications. Monitoring strategies include capillary glucose testing, continuous glucose monitoring (CGM), and glycated haemoglobin (HbA1c), each reflecting different aspects of glucose physiology.

Physiological Rationale for Glucose Monitoring

Plasma glucose is a dynamic variable influenced by:

• Hepatic glucose production (gluconeogenesis, glycogenolysis)

• Peripheral uptake (insulin-dependent in muscle/adipose via GLUT4)

• Dietary intake

• Counter-regulatory hormones (glucagon, cortisol, catecholamines)

Because glucose fluctuates on a minute-to-minute basis, single measurements cannot fully characterise glycaemic control. Monitoring aims to capture:

• Acute excursions → risk of hypoglycaemia/hyperglycaemia

• Chronic exposure → risk of complications via protein glycation and oxidative stress

Modalities of Glucose Assessment

1. Self-Monitoring of Blood Glucose (SMBG)

Measures capillary glucose at discrete time points.

Physiological relevance:

• Reflects real-time plasma glucose

• Enables immediate feedback for insulin dosing and behavioural adjustments

Limitations:

• Temporal sparsity → misses nocturnal hypoglycaemia and postprandial spikes

• Does not quantify glycaemic variability

2. Continuous Glucose Monitoring (CGM)

Measures interstitial glucose, which equilibrates with plasma glucose via diffusion.

Physiological considerations:

• Interstitial glucose lags behind plasma glucose by ~5–10 minutes

• Provides time-in-range (TIR), glycaemic variability, and trends

Advantages:

• Captures glucose excursions and variability, now recognised as independent contributors to oxidative stress and vascular damage [1]

  
  

3. HbA1c (Glycated Haemoglobin)

HbA1c is formed via non-enzymatic glycation of haemoglobin A at the N-terminal valine of the β-chain.

It reflects mean glycaemia over the lifespan of erythrocytes (~120 days), with a bias toward the preceding 4–6 weeks.

Mechanistic Basis of HbA1c Formation

Glucose binds haemoglobin via the Maillard reaction:

1. Formation of a reversible Schiff base

2. Rearrangement to a stable Amadori product (HbA1c)

The rate of formation is proportional to ambient glucose concentration, making HbA1c a surrogate of average glycaemia.

Advantages of HbA1c

• Integrates long-term glycaemic exposure

• Strong predictor of microvascular complications (retinopathy, nephropathy) [2]

• Low intra-individual variability

• No requirement for fasting

• 
  

Limitations of HbA1c

1. Inability to Capture Glycaemic Variability

HbA1c represents a time-weighted mean, not distribution.

• Equivalent HbA1c can arise from:

  • Stable normoglycaemia

  • Oscillations between hypo- and hyperglycaemia

Glycaemic variability contributes to reactive oxygen species (ROS) generation and endothelial dysfunction, independent of mean glucose [1].

2. Dependence on Erythrocyte Kinetics

HbA1c assumes normal red cell lifespan.

Falsely low HbA1c:

• Haemolysis

• Acute blood loss

• Chronic kidney disease (reduced RBC survival)

Falsely high HbA1c:

• Iron deficiency anaemia

• Reduced erythropoiesis

Thus, HbA1c reflects both glycaemia and erythrocyte turnover [3].

3. Inability to Detect Hypoglycaemia

HbA1c does not reflect frequency or severity of hypoglycaemia, a key determinant of morbidity in insulin-treated patients [4].

4. Temporal Insensitivity

Due to erythrocyte lifespan:

• HbA1c responds slowly to therapeutic changes

• Not suitable for short-term monitoring

  
  

5. Biological and Ethnic Variability

Differences in haemoglobin glycation rates and erythrocyte lifespan lead to discordance between HbA1c and mean glucose across individuals and ethnic groups [5].

Clinical Integration

Modern diabetes management emphasises complementary metrics:

• HbA1c → long-term complication risk

• CGM metrics (TIR, variability) → day-to-day control and safety

The concept of “time in range” (70–180 mg/dL / 3.9–10 mmol/L) has emerged as a clinically meaningful endpoint that addresses HbA1c limitations.

Conclusion

HbA1c remains a cornerstone biomarker due to its association with long-term outcomes. However, its inability to capture glycaemic variability, hypoglycaemia, and altered erythrocyte physiology limits its standalone utility. A mechanistic understanding of glucose dynamics supports the integration of real-time monitoring (SMBG/CGM) with HbA1c for comprehensive glycaemic assessment.

References

1. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, et al. Activation of oxidative stress by acute glucose fluctuations. JAMA. 2006;295(14):1681–1687.

2. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ. 2000;321(7258):405–412.

3. English E, Idris I, Smith G, Dhatariya K, Kilpatrick ES, John WG. The effect of anaemia on HbA1c. Diabetologia. 2015;58(7):1409–1421.

4. Cryer PE. Hypoglycemia in diabetes. Am J Med. 2005;118(9 Suppl):9S–18S.

5. Herman WH, Cohen RM. Racial and ethnic differences in HbA1c. Diabetes Care. 2012;35(12):e93.

Assessed and Endorsed by the MedReport Medical Review Board